Clinical trial
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00020579 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00020579 |
|---|---|
| Title | MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma |
| Official title | A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | entinostat |
| Enrollment | 75 |
| Start date | Mar 1, 2001 |
| Primary completion | Apr 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 15, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: